Rehmann Capital Advisory Group’s Puma Biotechnology PBYI Stock Holding History

Rehmann Capital Advisory Group’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$871	Hold	81	–	–	﹤0.01%	1579
2019 Q2	$1.03K	Hold	81	–	–	﹤0.01%	1922
2019 Q1	$3.14K	Hold	81	–	–	﹤0.01%	1642
2018 Q4	$1.65K	Hold	81	–	–	﹤0.01%	1516
2018 Q3	$3.71K	Sell	81 -6	-7%	-$289	﹤0.01%	1634
2018 Q2	$5.15K	Buy	87 +6	+7%	+$348	﹤0.01%	1537
2018 Q1	$6K	Buy	+81	New	+$6.07K	﹤0.01%	1469

Other funds holding PBYI

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rehmann Capital Advisory Group's PBYI Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Puma Biotechnology (PBYI) position steady in Q3 2019 at 81 shares worth $871. The position accounts for ﹤0.01% of the portfolio, ranked #1579.

Rehmann Capital Advisory Group first reported a position in PBYI in Q1 2018 and has held it in 7 quarters since. The position peaked at $6K in Q1 2018. 144 funds tracked by Wall St. Rank hold PBYI as of Q3 2019.

Rehmann Capital Advisory Group held 81 shares of Puma Biotechnology worth $871 as of Q3 2019.
Rehmann Capital Advisory Group left its Puma Biotechnology share count unchanged in Q3 2019.
Puma Biotechnology made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1579 holding.
Rehmann Capital Advisory Group first reported a position in Puma Biotechnology in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Puma Biotechnology position peaked at $6K in Q1 2018.
144 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.